Intensive Chemotherapy with Hematopoietic Cell Transplantation after ESHAP Therapy for Relapsed or Refractory Non-Hodgkin's Lymphoma. Results of a Single-Centre Study of 65 Patients

References

• Velasquez W. S., McLaughlin P., Tucker S., et al. ESHAP — an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4‐year follow‐up study. J. Clin. Oncol 1994; 12: 1169–76
   PubMed Web of Science ®Google Scholar
• Cabanillas F. Experience with salvage regimens at M. D. Anderson Hospital. Annals of Oncology 1991; 2: 31–32
   PubMed Web of Science ®Google Scholar
• Collins C., Mortimer J., Livingstone R. B. High‐dose cyclophosphamide in the treatment of refractory lymphomas and solid tumor malignancies. Cancer 1989; 63: 228–232
   PubMed Web of Science ®Google Scholar
• Soiffier S. J., Caliguiri M. A., Tondin C. High‐dose cytosine arabinoside in relapsed and refractory non‐Hodgkin's lymphoma. Cancer 1989; 64: 2014–2018
   PubMed Web of Science ®Google Scholar
• Cabanillas F., Hagemeister F. B., McLaughlin P., et al. Results of MIME salvage regimen for recurrent or refractory lymphoma. J. Clin. Oncol. 1987; 5: 407–12
   PubMed Web of Science ®Google Scholar
• Eghbali H., Catry T. I., Soubeyran P., et al. Combination of etoposide, cisplatin and ifosfamide (VPH) in the salvage chemotherapy of relapsing or refractory aggressive malignant lymphoma. Study of 51 patients. Bull. Cancer 1994; 81: 800–7
   PubMed Web of Science ®Google Scholar
• Buzzoni R., Colleoni M., Bajetta E., et al. Effective salvage chemotherapy in relapsed or refractory non‐Hodgkin's lymphoma. Annals. Oncol. 1993; 4: 251–3
   PubMed Web of Science ®Google Scholar
• Matsuura Y., Nakamura H., Kogure K., et al. A combination chemotherapy of mitoxantrone, etoposide, carbopl‐atin, and prednisolone (MECP) in recurrent or refractory non‐Hodgkin's lymphomas. Jap. J. Cancer. Chemother. 1994; 21: 237–41
   PubMedGoogle Scholar
• Richardson D. S., Tighe M., Cull G., et al. Salvage chemotherapy for relapsed and resistant lymphoma with a carboplatin containing schedule — EPIC. Hematol. Oncol. 1994; 12: 125–128
   PubMed Web of Science ®Google Scholar
• Okamoto M., Maruyama F., Tsuzuki M., et al. Salvage chemotherapy for relapsed/refractory aggressive non‐Hodgkin's lymphoma with a combination of dexametha‐sone, etoposide, ifosfamide and carboplatin. Rinsho Ketsueki 1994; 35: 635–41
   PubMedGoogle Scholar
• Ahmed T., Cook P., Feldman E., et al. Phase I‐II trial of high dose Ara‐C, carboplatinum, etoposide and steroids in patients with refractory or relapsed lymphomas. Leukemia 1994; 8: 531–4
   PubMed Web of Science ®Google Scholar
• Velasquez W. S., Cabanillas F., Salvador P., et al. Effective salvage therapy for lymphoma with cisplatin in combination with high‐dose Ara‐C and dexamethasone (DHAP). Blood 1988; 71: 117–122
   PubMed Web of Science ®Google Scholar
• Press O. W., Livingston R., Mortimer J., et al. Treatment of relapsed non Hodgkin's lymphomas with dexamethasone, high‐dose cytarabine, and cisplatin before marrow transplantation. J Clin. Oncol 1991; 9: 423–31
   PubMed Web of Science ®Google Scholar
• Rodriguez M. A., Cabanillas F., Velasquez W. Results of a salvage treatment program for relapsing lymphoma: MESNA‐ifosfamide, novantrone, and etoposide (MINE), consolidated with etoposide, solumedrol, high‐dose arabinoside and cisplatinum (ESHAP). J. Clin. Oncol. 1995; 13: 1734–1741
   PubMed Web of Science ®Google Scholar
• Bosly A., Coiffier B., Gisselbrecht C., et al. Bone marrow transplantation prolongs survival after relapse in aggressive‐lymphoma patients treated with the LNH‐84 regimen. J. Clin. Oncol. 1992; 10: 1615–23
   PubMed Web of Science ®Google Scholar
• Philip T., Armitage J. O., Spitzer G., et al. High‐dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate‐grade or high‐grade non Hodgkin's lymphoma. New. Engl J. Med. 1987; 316: 1493–1498
   PubMed Web of Science ®Google Scholar
• Velasquez W. S. ASHAP with or without ABMT for high‐risk non Hodgkin's lymphoma (NHL). Proc. Am. Soc. Clin. Oncol. 1995; 14: 387, abst
   Google Scholar
• Philip T., Guglxelmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy‐sensitive non Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Dreyfus R., Leblond V., Belanger C., et al. Peripheral blood stem cell collection and autografting in high risk lymphomas. Bone Marrow Transplant 1992; 10: 409–413
   PubMed Web of Science ®Google Scholar
• Bosly A., Sonet A., Salles G., et al. Superiority of late over early intensification in relapsing/refractory aggressive non Hodgkin's lymphoma: a randomized study from the GELA: LNH RP 93. Blood 1997; 80(suppl 1)2639, abst
   Google Scholar